‘The Price of Business’: Discussing the Latest Inflation Report
On July 12, Alex Brill joined Kevin Price on ‘The Price of Business’ to discuss the latest inflation report. What could be behind the significant drop?
Alex Brill Interviewed on the Future of the Adalimumab Market
MGA’s Alex Brill was interviewed by Mari Serebvrov for a new piece in BioWorld to discuss the latest with the adalimumab market as new competition is expected as early as July 1.
Taking Stock of the Humira Biosimilars Market
In January, the 21-year monopoly for AbbVie’s blockbuster drug Humira (adalimumab) came to an end with the launch of Amjevita, Amgen’s biosimilar adalimumab.
MGA’s Alex Brill on CNBC’s Squawk Box Discussing House Republican tax proposals
Alex Brill joined CNBC’s Squawk Box to discuss Biden’s billionaire tax policy proposal and why it is not desirable for the U.S. economy.
Analyzing the Build It in America Act: Proposals for Business Tax Reform
Last week, the House Committee on Ways and Means released three tax bills, and this week the Committee will meet to consider these measures.
- Patent Thicket Remedies
- Don’t Mix US Tax Administration Policy with the Israel-Hamas Conflict
- The Economics of “Delinking” PBM Compensation
- The Supreme Court Should Leave the Tax Code Alone
- Implications of Cannabis Legalization for the US Federal Budget
- Amicus Brief in Moore v. United States
- Biosimilars – Keys to Success in the Pharmacy Benefit
- New MGA White Paper Examines Consequences of Regulatory Uncertainty for Employee Ownership
- MGA Releases White Paper on Role of PBMs in US Drug Pricing Debate
- Unintended Consequences of Limiting PBMs
